Dr. Barta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
834 Walnut St
Ste 650
Philadelphia, PA 19107Phone+1 215-955-5161Fax+1 215-923-6003
Summary
- Dr. Julie Barta is a pulmonologist in Philadelphia, PA and is affiliated with Thomas Jefferson University Hospitals.
Education & Training
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 2011 - 2015
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2008 - 2011
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2008, MD
Certifications & Licensure
- PA State Medical License 2015 - 2024
- NY State Medical License 2011 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations Start of enrollment: 2021 May 05
Publications & Presentations
PubMed
- 817 citationsGlobal Epidemiology of Lung CancerJulie A. Barta, Charles A. Powell, Juan P. Wisnivesky
Annals of Global Health. 2019-01-22 - 62 citationsBlack patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up.Michael Lake, Christine S. Shusted, Hee Soon Juon, Russell K. McIntire, Charnita Zeigler-Johnson
BMC Cancer. 2020-06-16 - 11 citationsRacial Differences in Lung Cancer Screening Beliefs and Screening AdherenceJulie A. Barta, Christine S. Shusted, Brooke Ruane, Marcella Pimpinelli, Russell K. McIntire
Clinical Lung Cancer. 2021-06-13
Press Mentions
- More Black People Eligible for Lung Cancer Screening Under New GuidelinesSeptember 8th, 2022
- $225M Series B to Fund Delfi Diagnostics’ Early Cancer Detection Liquid Biopsy DevelopmentJuly 18th, 2022
- Updated USPSTF Lung Cancer Screening Criteria May Reduce Racial Inequalities in UptakeJune 27th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: